Launch BF: Astraea - Agents Accelerating clinical trials.

Astraea is an AI-agent startup (Joshua Wang, P26) that aims to accelerate clinical trials by automating data analysis and statistical programming end-to-end — ingesting raw study inputs and producing outputs intended to be FDA‑ready. Announced in the Bookface/Y Combinator digest on April 20, 2026 (tryastraea.com), the company frames its technology as an operational layer for regulated trial workflows, reducing manual statistical programming and regulatory-prep labor. The launch sits alongside other agent-first startups in the P26 cohort that focus on secure access, automation, and domain-specific verification; Astraea’s value proposition is tighter trial timelines and reproducible, submission‑grade deliverables through agentic pipeline automation for sponsors and CROs.